Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05715801
Other study ID # 2023-KLS-018-01
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 29, 2023
Est. completion date January 31, 2024

Study information

Verified date February 2023
Source The First Affiliated Hospital of Zhejiang Chinese Medical University
Contact Yan Jiang, M.D.
Phone 13575757710
Email jiangyan@zcmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 has swept the world, and while some people may experience long-term cognitive decline as a result of infection, no effective treatment has been announced. The primary goal of this study was to determine the efficacy of hyperbaric oxygen therapy in patients with SARS-CoV-2 infection, as well as to assess the effect of hyperbaric oxygen therapy on brain function in patients with COVID-19-related cognitive decline. In this study, approximately 80 people were randomly assigned to either hyperbaric oxygen or regular oxygen therapy to compare the effects of these two treatments on disease.


Description:

80 patients with cognitive impairment following a novel coronavirus infection will be randomly assigned to one of two treatment groups: hyperbaric oxygen therapy or conventional oxygen therapy. After the intervention, the improvement of hyperbaric oxygen on cognition, fatigue, sleep disorders, anxiety and depression, and other clinical manifestations was observed. The neurologic function of hyperbaric oxygen in the treatment of patients with cognitive decline after SARS-CoV-2 infection was also evaluated from imaging and electrophysiological multi-dimensional indexes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Out-patients 4 weeks after the diagnosis of SARS-CoV-2 infection - Subjective cognitive decline after SARS-CoV-2 infection - SARS-CoV-2 nucleic acid/antigen test negative. Exclusion Criteria: - Contraindications to hyperbaric oxygen therapy - Cognitive decline can be explained by other diseases - Conditions that researchers consider unsuitable for clinical trials.

Study Design


Intervention

Procedure:
hyperbaric oxygen therapy
The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
conventional oxygen therapy
Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)

Locations

Country Name City State
China First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary scores of Montreal Cognitive Scale (MoCA) The total score is 30 points, and the cut-off value for MCI is identified:=19 points(illiterate and primary school group);=22 points(Middle school group); =24 points(University group). The patients would be followed up for 3 months after oxygen therapy.
Secondary Quantitative Electroencephalography The main frequency distribution and absolute power spectrum of 4 frequency bands (d (1-3.9 Hz) , ? (4-7 Hz) , a (8-12.9 Hz) and ß (13-30 Hz) were obtained, the ? frequency and the relative power of d frequency (DTABR = (d + ?)/(a + ß)) were calculated. The patients would be followed up for 3 months after oxygen therapy.
Secondary Brain magnetic resonance imaging (MRI), brain functional magnetic resonance imaging (fMRI) The time series acquired from resting-state fMRI will be transformed into the frequency domain using Fast Fourier transform, and the square root of the power spectrum will be calculated and averaged across 0.01-0.08 Hz within each voxel.The ALFF of each voxel will be divided by the global mean ALFF value to standardize data across subjects. The patients would be followed up for 3 months after oxygen therapy.
Secondary Boston naming test Total score is 30 points.The cut-off values for each group are:?19(Junior high school education level),?21(High school education level),?22(University education level) The patients would be followed up for 3 months after oxygen therapy.
Secondary auditory verbal learning test,AVLT A 12-word list was repeated 3 times, and short-delayed recall was performed after an interval of 3-5 minutes, and long-delayed recall, cued recall and recognition were performed after an interval of 20 minutes. The most sensitive evaluation indexes were long-delayed recall score and recognition score. The auxiliary indexes included immediate recall score, total recall score, recall skills and discrimination. Cut-off values: long delayed recall score =5 (50-59 years), =4 (60-69 years), =3 (70-79 years);Recognition score =20 (50-59 years), =19 (60-69 years), =18 (70-79 years). The patients would be followed up for 3 months after oxygen therapy.
Secondary The Shape Trail Making Test A and B(STT-A&B) The Shape Trail Making Test A and B(STT-A&B) is divided into two parts: A and B. Each part includes exercises and tests. Part A asks participants to connect random numbers in sequence as quickly as possible. Part B asks participants to connect numbers in sequence alternately. Rating: Mainly record the amount of time spent. Cut-off value: STT-A test questions, 50~59 years old =70s, 60~69 years old =80s, 70~79 years old =100s;STT-B test questions, 50~59 years old =180s, 60~69 years old =200s, 70~79 years old =240s. The longer it takes, the worse it gets. The patients would be followed up for 3 months after oxygen therapy.
Secondary Animal word fluency (AFT) Subjects were asked to list as many examples of animals as possible within 1 min. Cut-off value: animal fluency score =12(junior high school group) , =13(senior high school group) , =14(university group) The patients would be followed up for 3 months after oxygen therapy.
Secondary Stroop color words test The stroop test lasts for 45 seconds, and the correct number of each test is calculated.Cut-off value: animal fluency score =12(junior high school group) , =13(senior high school group) , =14(university group) The patients would be followed up for 3 months after oxygen therapy.
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure